Can-Fite BioPharma American Depositary Shares
CANF
13 hedge funds and large institutions have $472K invested in Can-Fite BioPharma American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.
1.02% less ownership
Funds ownership: 2.42% → 1.4% (-1%)
13% less funds holding
Funds holding: 15 → 13 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
59% less capital inflows, than outflows
Capital inflows: $99.3K | Capital outflows: $244K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$76K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$8.31K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$1.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Advisor Networks
El Segundo,
California
|
-$169K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$36K |
| 3 |
Two Sigma Securities
New York
|
-$23K |
| 4 |
HRT Financial
New York
|
-$15K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1K |
CANF Hedge Fund Activity: Q1 2022 in Review
13 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2022, worth a combined $472K — down 25% from $626K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CANF and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $76K. The largest seller was Cetera Advisor Networks, exiting entirely with an estimated $169K sold.
- 13 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2022, down from 15 in Q4 2021.
- Funds reported $472K of Can-Fite BioPharma American Depositary Shares stock for Q1 2022, down 25% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2022 and 5 closed out, a net change of -2 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2022 was Morgan Stanley, an estimated $76K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2022 was Cetera Advisor Networks, an estimated $169K sold.
Based on aggregated 13F filings for Q1 2022.